ADC Therapeutics SA Cash Flow Statement
ADCT|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
ADC Therapeutics SA used $141M in operating cash flow and negative free cash flow of $141M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -4.83 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | -$142.6M | -$240.1M | -$157.1M |
| Depreciation & Amortization | - | $1.2M | $1.1M |
| Operating Cash Flow | -$141.2M | -$118.7M | -$138.3M |
| Capital Expenditures | $264.0K | $3.2M | $687.0K |
| Free Cash Flow | -$141.4M | -$121.9M | -$139.0M |
| FCF Margin | -173.8% | -175.3% | -66.2% |